Non-small cell lung cancer (NSCLC) is a common malignancy and is associated with poor survival outcomes. Biomarkers of systemic inflammation derived from blood tests collected as part of routine clinical care offer prognostic information for patients with NSCLC that may assist clinical decision making. They are an attractive tool, as they are inexpensive, easily measured, and reproducible in a variety of healthcare settings. Despite the wealth of evidence available to support them, these inflammatory biomarkers are not yet routinely used in clinical practice. In this narrative review, the key inflammatory indices reported in the literature and their prognostic significance in NSCLC are described. Key challenges limiting their clinical application are highlighted, including the need to define the optimal biomarker of systemic inflammation, a lack of understanding of the systemic inflammatory landscape of NSCLC as a heterogenous disease, and the lack of clinical relevance in reported outcomes. These challenges may be overcome with standardised recording and reporting of inflammatory biomarkers, clinicopathological factors, and survival outcomes. This will require a collaborative approach, to which this field of research lends itself. This work may be aided by the rise of data-driven research, including the potential to utilise modern electronic patient records and advanced data-analysis techniques.
非小细胞肺癌是一种常见的恶性肿瘤，其生存预后普遍较差。作为常规临床诊疗组成部分的血液检测所衍生的全身炎症生物标志物，可为非小细胞肺癌患者提供具有临床决策参考价值的预后信息。这类标志物因其成本低廉、检测便捷且在不同医疗场景下具有良好可重复性，成为极具吸引力的临床工具。尽管现有大量证据支持其应用价值，这些炎症生物标志物尚未在临床实践中得到常规使用。本叙述性综述系统阐述了文献报道的关键炎症指标及其在非小细胞肺癌中的预后意义，重点剖析了限制其临床应用的核心挑战：包括需明确最优的全身炎症生物标志物、对非小细胞肺癌作为异质性疾病所呈现的全身炎症特征认知不足，以及现有研究报道的结局指标缺乏临床相关性。通过标准化记录和报告炎症生物标志物、临床病理因素及生存结局，这些挑战有望得到解决。该领域研究天然适合采用协作研究模式，而数据驱动研究的兴起——包括利用现代电子病历系统和先进数据分析技术的潜力——将为这一工作提供有力支持。
肿瘤(癌症)患者之家